Showing 25 of 860 items meeting your criteria.
| | Type | Category | Supplier | |
|---|
| |
 | Xeno-free, serum-free media for human T cell cultivation |
Documents | Cell Culture | Xcell Therapeutics Inc. | |
 | Rapid & reliable detection of Niaph Virus via lateral flow. |
Documents | Virology | LeadGene Biomedical | |
 | Founded in 2018 as an academic spin-off based on unique DIANA technology for drug discovery and diagnostics, bringing deep expertise in molecular biology, chemistry and informatics. All operations are based in the heart of Europe: Prague, Czech Republic. With our expertise in protein engineering, we develop and produce unique and high-performance reagents for PCR, RT-PCR, RNA production, NGS and sample preparation in research, development and diagnostics. |
Documents | Catalogue | DIANA Biotechnologies | |
 | DBdirect PCR & qPCR mixes SuperSens 2.0 | DB SuperSens Taq DNA Polymerase | DB AptaTaq DNA Polymerase |
Documents | Molecular Biology | DIANA Biotechnologies | |
 | DB RNase Inhibitors | DBscript Reverse Transcriptase | Products for cDNA synthesis | One-Step DB RT-PCR & RT-qPCR mixes SuperSens 2.0 | One-Step DBdirect RT-qPCR mixes SuperSens 2.0 |
Documents | Molecular Biology | DIANA Biotechnologies | |
 | The most stable and potent inhibitor on the market. |
Documents | Molecular Biology | DIANA Biotechnologies | |
 | At DIANA Biotechnologies, we deliver top-quality custom DNA and RNA oligonucleotides tailored to your needs. With a wide range of modifications, we guarantee the highest purity, quality, and yield at competitive prices. |
Documents | Service | DIANA Biotechnologies | |
 | Fluorescent Dyes for High-Performance Labeling |
Documents | Dyes and Stains | DIANA Biotechnologies | |
 | Antibodies derived from alpacas or llamas with great penetrability and affinity to recognize novel epitopes. |
Documents | Antibodies | Abnova Corporation | |
 | Cloud-Clone provides high-quality raw materials to support global new drug development, biopharmaceutical companies, diagnostic reagent manufacturers, and CROs. |
Documents | Proteins | Cloud-Clone Corp. | |
 | Elabscience Uncoated ELISA Kits offer a versatile and cost-effective option that enables stable workflows while delivering high-quality results. |
Documents | ELISA | Elabscience | |
 | Tired of matrix effects in complex cell samples? The CellaQuant ELISA Kit overcomes traditional limitations to deliver high sensitive, specific and reliable results in challenging cellular matrices. |
Documents | ELISA | Elabscience | |
 | Optimized Efficiency, Low Toxicity |
Documents | Transfection | Elabscience | |
 | The optimal choice for pure and efficient exosome isolation |
Documents | Cell Culture | Elabscience | |
 | Cutting-Edge, Ready-to-Use Formulations for Seamless Cell Expansion |
Documents | Cell Culture | Elabscience | |
 | Classical to specialised - media that grow with your cell-based projects |
Documents | Cell Culture | Elabscience | |
 | Precision requires the right tools. Whether you are building complex neurovascular units or scaling xeno-free translational models, there is an OptiCulture™ serum-free system
designed for your specific microenvironment. |
Documents | Cell Culture | Cell Systems | |
 | Efficient Cell Isolation, Simple and Fast Workflow, High Compatibility, Reliable Quality |
Documents | Cell Based Assays | Elabscience | |
 | Empowering your neuroscience research. Accelerating drug discovery, development and translation for nervous system disorders. |
Documents | Neuroscience | iXCells Biotechnologies | |
 | T Cell Immunoreceptor with Immunoglobulin and ITIM domains (TIGIT, VSTM3) is an immune checkpoint receptor expressed on the surface of cytotoxic, memory and regulatory T cells
(Tregs) as well as natural killer (NK) cells. TIGIT binding to CD155 (PVR) and CD112 (Nectin-2) suppresses immune activation on cytotoxic T cells and NK cells. In the normal immune system, the suppressive effect of TIGIT is counterbalanced by the immune-activating receptor CD226 (DNAM1), which competes with TIGIT to bind CD155 and CD112. The inhibitory signal provided by TIGIT overpowers the ability of CD226 to stimulate T cell activation. Tumor cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction. Overexpression of TIGIT and reduced CD226 activity are frequently observed in exhausted T cells within tumors, making the TIGIT/CD226 axis a key focus for immune checkpoint blockade strategies. |
Documents | Immunology | AdipoGen Life Sciences | |
 | PD-1 (Programmed Cell Death Protein 1; CD279) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immune receptors. PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC;
CD273) are immuno-coinhibitory ligands of the B7 family binding to PD-1. The PD-1/PD-L1 or PD-L2 signaling pathway is a negative regulatory mechanism that inhibits T cell proliferation and cytokine production. Blockade of the PD-1/PD-L1 interaction enhances antitumor immunity. The PD-1 pathway plays a major role in the inhibition of self-reactive T cells and protection against autoimmune diseases. PD-1 and PD-L1 also exist as soluble forms. Elevated levels of soluble PD-1 (sPD-1) are shown in rheumatoid arthritis, skin sclerosis and autoimmune hepatitis. Levels of sPD-L1 are increased in the plasma of cancer patients as well as in cerebrospinal fluid of gliomas. sPD-L1 is a biomarker of poor survival in patients with B cell lymphoma, renal cell carcinoma, metastatic melanoma or lung cancer and is associated with advanced tumor stages. |
Documents | Immunology | AdipoGen Life Sciences | |
 | Beyond the well-characterized B7-1 (CD80), B7-2 (CD86) and PD-L1/PD-L2 pathways, newer B7 family ligands, B7-H3, B7- H4, B7-H5 (VISTA) and B7-H6, have emerged as important regulators of immune responses with significant interest in immunotherapy research. They are all overexpressed in tumors correlating with immune escape and resistance to antitumor
responses. |
Documents | Immunology | AdipoGen Life Sciences | |
 | The herpesvirus entry mediator (HVEM; CD270; TNFRSF14) represents a central hub in immune regulation, orchestrating complex interactions with multiple partners, including BTLA, LIGHT
and CD160. HVEM is a molecular switch that acts both as an immune system stimulator and as an inhibitor. It is expressed in T cells, B cells, natural killer cells, dendritic cells and endothelial cells. LIGHT is an immune stimulator that contributes to dendritic cell maturation and T cell expansion. The immune suppressor BTLA functions in opposition to LIGHT by inhibiting naïve T cell expansion and induction of Treg cells. CD160 acts as an immune suppressor through its interactions with HVEM. The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions that function in both immune stimulation and suppression and which is a potential therapeutic target for treatment of autoimmune diseases and allergies and controlling antitumor responses. |
Documents | Immunology | AdipoGen Life Sciences | |
 | OX40 (CD134; TNFRSF4) is an activating receptor, a member of the TNF receptor superfamily, expressed on the surface of activated cytotoxic T cells and regulatory T cells (Tregs). OX40 both activates and amplifies T cell responses. On cytotoxic T cells, OX40 binds to its ligand OX40L (CD252; TNFSF4), resulting in stimulatory signals that promote T cell reproduction, function and survival. OX40/OX40L signaling blocks the ability of Tregs to suppress T cells and reduces Treg generation. By inhibiting the immunosuppressive effect of Tregs and limiting their population, OX40 further amplifies the impact of T cell activation. The dual effects of OX40 help to create a tumor microenvironment that is more favorable to the antitumor immune response. The OX40-OX40L axis is a versatile and promising target across oncology, autoimmunity, and chronic inflammatory disease research. |
Documents | Immunology | AdipoGen Life Sciences | |
 | Inducible T Cell Co-Stimulator (ICOS; CD278) is an activating receptor expressed on the surface of activated cytotoxic T cells, regulatory T cells (Tregs), natural killer (NK) cells and other types of T cells, having a distinct and opposing function than CTLA-4. The ligand ICOSL (B7-H2; CD275) is expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. ICOS/ICOSL signaling leads to the activation, proliferation and survival of cytotoxic T cells, as well as the survival of memory T cells. ICOS/ICOSL binding generates various activities including T cell activation and effector functions and when sustained also suppressive activities mediated by regulatory T cells. This dual role in both anti-tumor and pro-tumor activities makes targeting the ICOS/ICOSL pathway attractive for enhancement of anti-tumor immune responses and as a potential biomarker for disease treatment and prognostic prediction. |
Documents | Immunology | AdipoGen Life Sciences | |